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ABSTRACT 
The Role of Inflammation and Oxidative Stress in Total Hip Replacement Revisions: 
Development of a Diagnostic Panel for Osteolysis 
Lauren Jo Jablonowski 
 
 
 
 
In the United States, the standard of care for degenerative joint disease is total 
joint replacement (TJR) with over 600,000 total hip and knee replacements performed 
each year. However, roughly 20% of these surgeries require a revision surgery as a 
result of tissue reactions to polyethylene wear debris. The reaction to wear debris 
stimulates an inflammatory response that initiates and promotes osteolysis, a 
progressive inflammatory-mediated bone resorptive disease. The goal of this study was 
to identify inflammatory and oxidative stress specific proteins and products involved in 
the development of osteolysis in revised total joint replacement tissues. 
Polarized light microscopy was used to determine the number of polyethylene 
particles embedded in total hip replacement (THR) revision tissues as a result of 
implant wear. Tissues from patients with increased amounts of osteolysis showed an 
average of 51.8 ± 36.8 particles per mm2 of tissue (Groups 1-3; increasing severity of 
osteolysis), while non-osteolytic tissues (control, Group 4) contained 1.5 ± 0.3 particles 
per mm2 of tissue. Inflammation was present in all osteolytic tissues, and to a lesser 
extent in control tissues.  
Immunohistochemistry was used to compare the severity of osteolysis with 
high mobility group protein B1 (HMGB1), reactive oxygen species (ROS) enzyme 
cyclooxygenase-2 (COX2), reactive nitrogen species (RNS) enzyme inducible nitric 
oxide synthase (iNOS), and their oxidized products 4-hydroxynonenal (4-HNE) and 
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nitrotyrosine (Nitro, NT). Pearson’s correlation coefficient and principle component 
analysis were performed. Results from the most severe osteolytic group (Group 1) 
showed significant correlations between increased vascularity and 4HNE, COX2, 
iNOS. Both severe and moderate osteolytic tissue groups (Groups 1 and 2) showed a 
strong correlation between particle number and HMBG1. Interestingly, patients in the 
low radiographic osteolysis group (Group 3) exhibited increased 4HNE and COX2, 
whereas this relationship was replaced by correlations of HMGB1 with iNOS in tissues 
from patients with more severe osteolysis. The confirmed presence of ROS/RNS 
enzymes and products indicates oxidative stress is involved in the development of 
osteolysis.  
Building on the current findings, this study also includes the design of a genetic 
array and protein panel for the early diagnosis of THR osteolysis. The proposed 
designs are primarily based on the immunohistochemistry results, as well as review 
articles discussing genes associated with osteoclasts, osteoblasts and oxidative stress. 
The genes and proteins can be broken into five main categories: osteoclast-related, 
osteoblast-related, oxidative stress-related, inflammation-related, and controls. For the 
genetic array, 27 genes were selected for their involvement in osteoclast, osteoblast 
differentiation and function, as well the involvement of oxidative stress in osteolysis, 
along with 5 control elements. Similarly, for the protein panel, 28 proteins and 
oxidized products were selected for their involvement in osteoclast and osteoblast 
differentiation, oxidative stress, and osteolysis. Additionally, two protein controls were 
included for tissue or serum normalization of each factor.  Serum samples will be 
collected from TJR patients using a standard blood collection protocol, and will be 
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screened regularly for the presence of identified biomarkers in an attempt to obtain an 
early indication of osteolysis.  
Ultimately, the genetic array and protein panel for genes and proteins associated 
with oxidative stress could potentially be used for both early diagnosis and to identify 
potential therapeutic targets to treat osteolysis in TJR patients.  
 
 	  
0	  
 
 
	  
 	  
1	  
1. INTRODUCTION 
1.1 Anatomy and Joint Pathologies 
The human hip joint, a ball and socket joint, is comprised of two main 
components: the acetabulum and the femoral head (Figure 1). The femoral head, 
topping the femur bone, fits into and articulates within the acetabulum of the pelvis. 
This joint is surrounded by capsular ligaments and tissues, which maintain the 
alignment and determine the range of motion of the joint.  
 
 
 
Figure 1: Diagram of the human hip joint (dislocated for visualization). Modified from Anatomy of 
the Human Body, Lea & Febiger © 1918 [1]. 
 
 
 
 Throughout life, skeletal bones are continually remodeled to maintain bone 
strength. According to Wolff’s Law, the remodeling process is the result of osteoclast 
and osteoblast responses to the magnitude and direction of the load [2]. Osteoblasts, 
Femoral	  Head	  
Acetabulum	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bone-producing cells, are generally kept in balance with osteoclasts, which remove 
bone during the remodeling process. As humans age, several pathologies can cause 
detrimental effects to the structure and composition of skeletal bone. One of the more 
prevalent pathologies, especially for older women, is osteoporosis, a condition in 
which osteocytes undergo apoptosis in an unregulated fashion, osteoclast activity is 
increased and/or osteoblast activity is decreased [2]. Osteoporosis, or low-density bone, 
weakens the bone structure and makes its susceptible to fracture. However, 
osteoarthritis and degenerative joint disease represent the two most common hip 
pathologies, ultimately requiring total hip replacement (THR) surgery.  
1.2 Total Hip Arthroplasty 
Total joint replacement (TJR) is the standard of care for advanced degenerative 
joint disease in the United States, with over 600,000 total hip (THR) and total knee 
replacements (TKR) being performed each year [3]. It is projected that the number of 
annual TJR surgeries will exceed 4,000,000 by the year 2030 [3].  
1.2.1 Brief History 
In 1961, Dr. John Charnley developed the first modern hip replacement 
implant, using high-density polyethylene (PE) as a bearing surface, stabilized by 
acrylic bone cement [4]. Dr. Bernhard Weber and others, improved upon this design by 
incorporating stronger femoral stems, rotational reduction of friction, and metal-on-
metal articulation surfaces [5-7]. Current metal THR implant designs are similar to 
these original THR devices, although they differ slightly in design and shape, and also 
in metal composition, containing combinations of titanium, cobalt, and chrome as the 
three major metals.  
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In contrast, the polyethylene (PE) component has undergone a number of 
sterilization and crosslinking changes. Originally, the acetabular liner components were 
composed of high-density polyethylene (HDPE). However, in 1998, manufacturers 
began using highly-crosslinked ultra-high molecular weight polyethylene (UHMWPE) 
instead of the conventional HDPE [8]. Studies have shown that this new UHMWPE 
material effectively reduces the size of PE wear debris particles present in 
periprosthetic tissues [9-12]. However, while the number of larger PE particles is 
reduced, the number of submicron-sized wear particles, which stimulate a more robust 
inflammatory response, are increased [9]. Several in vitro studies have shown that 
exposure to UHMWPE wear debris within a specific size range (0.1-1µm) results in 
enhanced macrophage activation [13-15]. Therefore, despite these material 
improvements, some THR patients may experience complications after long-term 
implant use.  
1.2.2 Outcomes and Complications 
Even though complications after joint replacement are relatively low, 
approximately 20% of all TJR surgeries result in reoperations, where the implant must 
be replaced or other interventions must be taken to restore mobility [16, 17]. 
Specifically, revision surgery for aseptic, or non-infected, implant loosening and/or 
osteolysis in response to PE wear debris in periprosthetic tissues is a major problem 
that limits THR longevity in the United States [17, 18]. Due to the loss of the 
surrounding bone, revision surgeries often have poorer outcomes. Thus, early diagnosis 
and treatment to reduce the number of revision surgeries would significantly improve 
patient quality of life and reduce the economic burden. 
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1.3 Osteolysis 
1.3.1 Condition Overview 
 As stated above, periprosthetic osteolysis is considered the foremost 
complication limiting the longevity of THRs [17, 18]. Implant osteolysis is an 
inflammatory-mediated bone resorption process, stimulated by the production of 
implant wear debris [17]. Progressive bone loss at the bone-implant interface results in 
implant loosening, instability, and ultimately the need for revision surgery [17]. Studies 
have shown that the presence of PE wear particles from the articulation of metal-on-PE 
joint replacements is the main cause of periprosthetic osteolysis. Patients revised for 
osteolysis consistently have PE particle quantities on the order of 109 particles per 
gram weight of tissue [19-21].  
Macrophages, and to a lesser extent neutrophils, ingest or phagocytose 
biologically-indestructible PE wear particles. Ingestion stimulates the production and 
release of pro-inflammatory factors that promote the influx and activation of additional 
inflammatory cells [9, 15, 22]. In vitro, macrophage ingestion of wear debris leads to 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation [23, 
24]. These responses to PE debris ingestion stimulate an inflammatory cascade that can 
ultimately promote osteoclastogenesis and osteoclast activation (Figure 2). The 
production of ROS by macrophages and their involvement in mediating osteolysis in 
TJR revision cases has not been determined.  
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Figure 2: Cellular and molecular regulation of wear debris-induced osteoclastogenesis. Positive (+) 
and negative (-) effects of wear debris are shown throughout the cascade. Reprinted with 
permission from Springer. [25] 
 
 
1.3.2 Inflammatory Response 
The inflammatory response to PE wear debris is a major contributor to the 
development of chronic inflammation and the increased incidence of osteolysis [17]. 
Interactions between PE wear particles and resident cells, such as macrophages, 
fibroblasts, osteoblasts, osteoclasts, and possibly T-cells, contribute to the development 
of osteolysis and ultimately implant loosening [17, 26-30]. A diagram of resident and 
recruited cells is shown in Figure 3. Based on numerous studies of periprosthetic 
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tissues, researchers have determined that the activation of both recruited and resident 
cells leads to the production and release of inflammatory cytokines, chemokines, and 
growth factors that affect osteoclast and osteoblast activity [17, 25-30].  
 
 
 
 
Figure 3: Schematic of osteolytic response. Macrophages, fibroblasts, osteoclasts/osteoblasts, and 
T-cells all play a role in the development and progression of osteolysis. 
  
 
 
Several recent studies suggest that particle recognition, binding, phagocytosis 
and macrophage activation occurs through several receptors, including toll-like 
receptors (TLR) 2 and 5 and macrophage receptor with collagenous structure 
(MARCO) [31-33]. The alternative, or anti-inflammatory, macrophage activation 
pathway has also been implicated in increased osteoclast differentiation and reduced 
osteogenic stimulus expression based on periprosthetic tissue genetic profiling studies 
[34, 35]. Alternative macrophage pathway activation results in the release of the pro-
inflammatory factors interleukin-8 (IL-8) and macrophage inflammatory protein 1α 
(MIP-1α) [34-36].  Both of these proteins may directly or indirectly affect bone 
resorption and periprosthetic osteolysis [34-36]. 
Osteolytic	  Response	  
Macrophages	   Fibroblasts	   Osteoclasts/Osteoblasts	   T-­‐Cells	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Macrophages and fibroblasts in periprosthetic tissues release soluble products 
in response to PE wear debris, these products do little to remove the debris but 
unintentionally affect the activity, proliferation, and differentiation of osteoclasts and 
osteoblasts [17, 37-39]. Additionally, resident macrophages have the potential to 
differentiate into fully functional osteoclasts in response to wear debris [29]. 
Osteoclasts are formed from precursor cells in response to binding of nuclear factor 
kappa B ligand (RANKL) and monocyte colony stimulating factor (M-CSF) [40-42]. 
Osteoclast activity is also promoted by the pro-inflammatory cytokine IL-6 release 
from activated fibroblasts and macrophages [43]. In addition, studies have shown that 
the presence of PE wear debris reduces matrix production by osteoblasts, thereby 
contributing to overall bone loss [17, 26, 27].  
T cells, as a part of the adaptive immune response, have also been observed in 
periprosthetic tissues and implicated in the wear debris-mediated inflammatory 
response. These cells are predominantly involved in metal wear debris foreign body 
inflammatory responses [28, 44]. However, two chemoattractants of activated TH1 
cells, interferon-γ-inducible protein 10kDa (IP-10) and interferon-γ-induced monokine, 
as well as IL-8 have been observed in periprosthetic tissue [36].  
1.3.3 Oxidative Stress and Osteolysis 
 The involvement of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) activation and generation in response to PE wear debris has been studied 
in vitro, but understanding their involvement in TJR complications is lacking. The 
overproduction or inadequate removal of ROS/RNS, known as oxidative stress, has 
been implicated in the formation of fibrotic pseudocapsular tissues around revised, 
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THR components [45]. Specifically, oxidative stress-induced protein modification, 
lipid oxidation, and DNA hydroxylation lead to altered gene expression, altered cell 
and matrix interactions, and irreparable tissue injury, fibrosis and/or necrosis [46, 47]. 
These responses are not unexpected as phagocytosis of PE wear debris activates 
macrophages, initiating the generation of ROS by NADPH-oxidase (NOX) and RNS 
by inducible nitric oxide synthase (iNOS) [23, 24]. More importantly, ROS are known 
to be involved in mediating osteoclast differentiation, and to play an essential role in 
the bone resorption process, and as such potentially TJR osteolysis (Figure 4) [42, 48-
51].  
 
  
 
 
Figure 4: Normal bone remodeling (left) and oxidative stress-induced bone resorption (right). 
Reprinted with permission from Elsevier [42].  
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Figure 4 illustrates the difference between osteoclast differentiation in normal 
bone resorption (left) and oxidative stress-induced increased osteoclastogenesis and 
bone resorption (right) [42]. When osteoblasts express RANKL in the presence of M-
CSF, bone precursor cells differentiate into multinucleated osteoclasts [42]. Binding of 
RANKL to its receptor RANK on osteoclast precursors stimulates cell-specific gene 
expression, fusion, activation, and bone resorption [42]. In normal bone remodeling, 
osteoblasts also express osteoprotegerin (OPG), a decoy receptor for RANKL, which 
effectively suppresses osteoclast differentiation [42, 52]. However, in oxidative stress 
conditions, reduced amounts of OPG are produced, altering the ratio of RANKL and 
OPG, disrupting the balance between osteoblast and osteoclast activity, and leading to 
predominantly bone resorption activity [42, 52].  
 Based on the implication of oxidative stress in wear particle-induced bone 
resorption and osteolysis, this study focuses on five specific oxidative stress 
biomarkers. First, high mobility group protein B1 (HMGB1), a cytokine produced by 
macrophages and osteoblasts that promotes osteoclastogenesis, was evaluated as a 
general osteolytic marker [53, 54]. The expression of this factor is also increased in 
response to oxidative stress. Oxidative stress responsive and ROS-producing enzyme, 
cyclooxygenase-2 (COX2) and oxidized product 4-hydroxynonenal (4-HNE) were also 
evaluated for their potential roles in wear debris-mediated inflammation and bone 
resorption [55-57]. Finally, the RNS enzyme inducible nitric oxide synthase (iNOS) 
and its RNS product nitrotyrosine (Nitro, NT) were evaluated based on their potential 
role in oxidative stress-mediated osteolysis [58]. iNOS expression has been shown to 
increase proportionally with the extent of osteolysis [59]. NT is associated with wear 
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debris-induced inflammation [60], requiring both ROS and RNS production for its 
generation. Evaluation of these five factors provided an evaluation of oxidative stress 
mechanisms potentially involved in PE wear debris-mediated periprosthetic osteolysis.  
1.4 Current Treatment and Significance 
 Currently, no established, validated methods exist to simulate long-term clinical 
performance of THR implant materials and devices. Additionally, there is no 
diagnostic assay specific for the diagnosis of osteolysis in THR patients. During 
clinical follow-up, surgeons rely on planar radiographs to evaluate the quality of bone 
at the fixation interface; whereas intraoperative findings provide a more definitive 
diagnosis of osteolysis, but only at the time of revision surgery. A more sensitive and 
inexpensive method is needed to better define osteolysis, preferably at a time when 
treatment could be provided to reverse and/or prevent further bone resorption.  
 Previous studies, while documenting the ability of wear debris to activate pro-
inflammatory signaling cascades, have only focused on a limited number of 
inflammatory factors. As such, the full repertoire of wear debris-mediated responses 
involved in THR complications, specifically osteolysis, have not been established. 
More importantly, current in vivo animal and in vitro cell culture models used in an 
attempt to understand wear debris-mediated inflammation and osteolysis are 
inadequate and ineffective in recapitulating the long-term complications associated 
with clinical THR implant failure in human patients.  
 Therefore, the collection and analysis of periprosthetic tissues retrieved during 
THR revision surgery is a vital and necessary tool for the characterization and 
understanding of the biological response to wear debris. The characterization and 
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understanding of pathophysiologic changes and specific biomarkers may lead to the 
development of predictive and preventative measures, by means of biomarker panels 
and pharmacological modulators, to ameliorate wear debris-associated osteolysis in 
THR patients.  
1.5 Problem Statement 
As stated previously, over 600,000 TJR surgeries are performed within the 
United States each year, with the expectation to reach over 4,000,000 by the year 2030 
[3]. However, despite the prevalence of these interventions, approximately 20% of TJR 
patients require revision surgeries due to complications [3]. Revision surgery for wear 
debris-mediated implant loosening and/or osteolysis is considered one of the major 
problems limiting TJR implant longevity [17, 18]. Importantly, no clinical device 
currently exists for early diagnosis of osteolysis, and radiographs are not sufficiently 
sensitive to detect osteolysis until it is advanced. Specific to this study, understanding 
the mechanisms involved in the early stages of osteolysis may allow the development 
of a diagnostic panel and an understanding of potential therapeutic interventions.  
The central hypothesis of this research project is that PE wear debris generated 
from THR implant components stimulates a unique response. This response involves 
both inflammation and inflammatory-mediated oxidative stress, which ultimately 
initiate and promote osteolysis. The main goal of this study was to identify 
inflammatory- and oxidative stress-specific biomarkers in THR revision tissues. Once 
identified, the pathways, genes, and proteins associated with these molecular changes 
can be used to develop a diagnostic panel. The panel could then be used in the 
following situations: (1) to screen for a predisposition for developing osteolysis, or (2) 
 	  
12	  
to identify the presence of early osteolysis around implanted components based on an 
increase in specific biomarkers in TJR patient serum. Additionally, these biomarkers 
could eventually be targeted as a therapy to reduce or prevent osteolysis in THR 
patients, thus preventing the need for revision surgeries and improving overall implant 
longevity.   
1.6 Specific Aims 
The specific aims of this study were:  
(1) To determine the potential mechanisms of inflammation-induced osteolysis 
in THR revision periprosthetic tissue. PE wear debris-induced inflammatory 
and immunohistochemical biomarkers were identified and quantified, using 
brightfield imaging and NIH ImageJ analysis software, in tissues from THR 
revision patients with varying levels of osteolysis. Correlation of these 
potential biomarkers with the extent of osteolysis was determined with 
regression, Pearson’s coefficient, and principle component (PCA) analyses.   
(2) To design a genetic array for determining potential oxidative stress 
pathways involved in mediating osteolysis in revision tissues. Once 
identified, oxidative stress and osteolytic biomarkers were compiled into a 
genetic array, designed to identify important regulatory genes that are either 
upregulated or downregulated in revision tissues using RT-PCR analysis. 
This array will be used to verify and validate the involvement of oxidative 
stress in mediating THR osteolysis and to identify potential biomarkers in 
the current and additional revision tissue samples.   
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(3) To design a protein panel for an effective, and non-invasive, diagnostic test 
to detect early osteolysis in THR patients. This panel, designed analogous to 
the genetic array in Specific Aim 2, will be used to initially screen revision 
tissues and serum from patients with varying amounts of osteolysis, and 
ultimately serum samples from primary THR patients. The primary THR 
patients will be screened at specific intervals to detect early onset osteolysis 
and to determine their risk for developing extensive osteolysis. As with the 
genetic array, verification and validation of this design will require 
additional revision sample analyses to confirm accuracy and sensitivity. 
During these verification and validation studies, a subset of the selected 
proteins is expected to be consistently elevated in the serum, and in this way 
predictive of osteolysis, thus reducing the number of proteins to be 
evaluated and the overall cost of evaluation.  
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2. EXPERIMENTAL METHODS AND MATERIALS 
2.1 Tissue Sample Selection 
Hip capsule tissue specimens were retrieved from 19 revised THR patients with 
varying degrees of osteolysis, shown in Appendix A. Group 1 included six patients 
with severe osteolysis (implantation time 11.47-19.80 years; average of 16.04 years). 
Group 2 included four moderate osteolysis patients, with an average implantation time 
of 16.68 years (range of 10.80-25.04 years). Group 3, low osteolysis, included seven 
patients with an average implantation time of 15.97 years (range of 5.08-20.17 years). 
Finally, two non-osteolytic control patients (Group 4) had an average implantation time 
of 4.05 years (range of 2.93-5.17 years).  
In total, 48 tissue specimens were processed and evaluated during this project. 
All tissue specimens were collected by participating surgeons from the Rothman 
Institute at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, under 
appropriate IRB protocols through Drexel University and the Drexel Implant Research 
Center. All identifying information was removed from the samples before acquisition 
by the Drexel Implant Research Center, according to Health Insurance Portability and 
Accountability Act (HIPAA) regulations.  
2.1.1 Sample Inclusion Criteria 
Inclusion in this study was based on several factors, the first of which was 
patient consent to participate in any studies conducted by the Drexel Implant Research 
Center. To standardize the type of bearing surface material, the second inclusion 
criterion was that the patient had received a conventional, gamma-air sterilized THR 
polyethylene component. Third, it was verified that both clinical information and 
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radiographs were available to assess the intraoperative and radiographic evidence of 
osteolysis. Finally, at least a gram of tissue needed to be available for 
immunohistological (paraffin-embedded), RNA array, and protein array analyses to be 
included in this study. 
Exclusion criteria included an implantation time of less than one year, revision 
for infection, a previous revision surgery, expired consent, a cemented implant, and/or 
intraoperative information or radiographs were unavailable after request. In addition, 
patients were excluded if bone loss was due to stress shielding rather than osteolysis. 
Radiographs were scored by Dr. Javad Parvizi with the Rothman Institute to determine 
the extent and location of radiographic osteolysis. 
2.1.2 Radiograph Scoring 
Serial anteroposterior and lateral radiographs of the affected hip joint of all 19 
study patients were reviewed by Dr. Parvizi to assess the position of prosthesis, 
loosening and wear, and osteolysis. Loosened components were defined as those that 
demonstrated a complete lucent line on any radiograph, femoral subsidence of 2 mm or 
more, or acetabular component migration or tilt. Osteolysis was defined by lucent areas 
adjacent to the implanted device in acetabular and femoral zones. The femur was 
divided into seven zones and the acetabulum into three zones to evaluate the location of 
lucent lines of osteolysis [4, 61-64]. Below, Figure 5 shows one of the anteroposterior 
radiographs from a patient with severe osteolysis. In this radiograph, the patient shows 
moderate osteolysis in acetabular zones I-III, and severe osteolysis in femoral zones I-
III, VI, and VII.  
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Figure 5: Patient radiograph showing severe osteolysis (implantation time 25 years) and 
radiographic zone reference. (Left) Radiograph of a right hip replacement with severe femoral 
osteolysis, and moderate acetabular osteolysis, contributing to implant loosening. Areas of darker 
gray surrounding the implant are osteolytic lesions, with darkness correlating to osteolytic 
severity. (Right) Radiographic zone reference, modified from Radiologic Guide to Medical Devices 
and Foreign Bodies, Mosby-Year © 1994 [65]. 
 
 
 
This scoring information, coupled with the intraoperative observations of 
osteolysis indicated in the clinical notes, was then used to separate patients into the 
four groups (Appendix A). Six patients who received an “extensive osteolysis” or had a 
large (> 2 mm) amount of osteolysis based on radiographic scoring were placed in the 
Severe Osteolysis group, or Group 1. Four patients were placed into Group 2, as these 
patients received a “some osteolysis” or had a small (< 2 mm) amount of osteolysis 
based on radiographic scoring and were placed in the Moderate Osteolysis group. 
Seven patients were given a “no osteolysis” radiograph score, but had an intraoperative 
observation of osteolysis; these patients were placed into the Low Osteolysis group 
(Group 3). Finally, two patients who had neither a radiographic scoring of osteolysis 
nor an intraoperative observation of osteolysis were placed into the Control group, or 
Group 4.   
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2.2 Tissue Sample Preparation 
Tissue specimens were excised from the hip capsular region adjacent to the 
implanted device during THR revision surgery. Clinical information regarding the 
patients in each group, such as implantation time and gender, are summarized in 
Appendix A.  Retrieved tissues were fixed in Universal Tissue Fixative (Sakura 
Finetek USA) in the operating room, and were transferred to 70% ethanol within 4 
days of arrival in the Drexel Implant Research Center laboratory. Fixed tissues were 
embedded in paraffin, and 6µm serial sections were mounted onto Fisher 
Superfrost/Plus slides and used for histological and immunohistochemical staining.  
2.3 Histomorphology Staining 
Slides were dewaxed, rehydrated, and stained with acidified hematoxylin and 
eosin (H&E) (Fisher Scientific). Slides were coverslipped and imaged for morphology, 
vascularization, and inflammation. Brightfield microscopy was used to visualize 
inflammation in response to implant wear debris. Polarized light microscopy was used 
to determine the number of polyethylene particles embedded in tissues as a result of 
implant wear. Both of these imaging techniques will be discussed in depth in the 
imaging section below. The results from the H&E stains were used to verify the 
presence of inflammation in the study tissues.  
2.4 Immunohistochemistry 
Immunohistochemistry was performed on slides prepared to evaluate the 
presence of osteolysis (HMGB1, Rabbit IgG, Abcam), reactive oxygen species (COX2, 
Mouse IgG1, Abcam), reactive nitrogen species (iNOS, Mouse IgG1, R&D Systems), 
and their oxidized products (4-HNE, Mouse IgG1, Percipio Biosciences and NT, 
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Mouse IgG3, R&D Systems). Data sheets for each of these immunohistochemical 
antibodies are included in Appendix B-F, respectively.  
2.4.1 Antibody Optimizations 
To determine the optimal conditions for staining with each antibody, a series of 
optimization experiments was performed on test slides tissues retrieved from patients 
with stiff knee syndrome/arthrofibrosis, and bone marrow. Immunohistochemistry with 
antibody concentrations of 1:50, 1:100, and 1:200 were performed on these slides using 
the standard immunohistochemistry protocol detailed below. The slides were evaluated 
for the intensity of staining, and the optimal antibody concentrations were selected as 
follows: 4-HNE at a concentration of 1:50, COX2 at a concentration of 1:100, HMGB1 
at 1:200, iNOS at 1:50, and NT at a concentration of 1:100.  
2.4.2 Immunohistochemical Staining 
One slide for each tissue sample was prepared for each immunohistochemical 
stain, and the following process was repeated for each antibody to be evaluated. Slides 
were dewaxed and rehydrated in preparation for the immunohistochemical staining 
protocol. Slides were incubated in an antigen retrieval solution (Vector Labs), followed 
by incubation in 0.5% Triton in PBS in enhance permeability. Then, slides were 
incubated in 3% hydrogen peroxide in methanol to block endogenous peroxidases, 
followed by blocking for non-specific background staining in a 4% BSA in PBS with 
0.1% Tween 20 solution. After these preparatory steps were completed, the diluted 
primary antibody was applied to each tissue sample, then samples were coverslipped 
and incubated at 4°C overnight. Following this incubation, the samples were incubated 
with the pan-specific secondary antibody, and then treated with horseradish peroxidase 
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(Santa Cruz Biotech) and DAB solution (Vector Labs) for antibody visualization. 
Finally, slides were counterstained with acidified hematoxylin for nuclear visualization 
and coverslipped for imaging.  
2.5 Sample Imaging 
Slides were imaged using an Olympus BX50 microscope, equipped with a 
stepper motor controlled stage, an elliptically polarized light imaging system (EPLIS), 
and a PixeLINK microscope camera, generously provided by Dr. Todd Doehring’s 
laboratory.  
2.5.1 Microscope Assembly and Calibration 
With each use, the microscope was set up and calibrated for tissue imaging. To 
perform the imaging process, the following settings had to be determined. First, the 
stage must be assembled with the slide holder firmly in place, and the 10x objective 
was installed. Once a slide is in place, the large focus knob was adjusted to bring the 
stage within 1mm from the objective. The microscope and the PixeLINK computer 
interface are then turned on, microscope light setting was set to 8, the EPLIS filter is 
set to 90 degrees, and communication between the two systems was confirmed by 
visualization of the field on the computer screen. The fine focus was adjusted until the 
tissue sample appears to be focused on the computer screen.  
Next, the light transmission was calibrated, to ensure that all light was 
converging at the level of the sample on the stage. The light aperture was almost 
completely closed to ensure that light was focused on one spot on the sample. This 
appeared as a small dot on the computer screen image. Then, the stage knob was 
adjusted so that the image in the shape of a 9-sided figure appeared sharply within the 
 	  
20	  
focused light. Once this 9-sided figure had sharp, defined edges, the alignment knobs 
were adjusted until the 9-sided figure appeared in the middle of the computer interface 
window, signifying that the light was focused in the center of the sample. The aperture 
was then fully re-opened and the sample specific light calibration could be performed.  
2.5.2 Image Acquisition 
The light was calibrated for each individual tissue sample, as collagen density 
and staining intensity affect the lighting of each sample. Additionally, the bottom 
filters had to be set to the following: LBD closed, ND6 open, and ND25 closed. Then, 
the following settings were entered into the PixeLINK interface: Exposure Time of 70, 
Gain 1.6, Saturation 120, Gamma Off, Frame Rate Off, Color Temp 5000, and Size 
3000x2208 pixels. At this time, the slide should be aligned to the site of the first image 
to be collected, and a white balance should be performed.  
After all of the calibration steps were complete, the image array was 
programmed and performed. The stepper motor power supply was turned on, and the 
PixScanner computer interface was opened to activate the stepper motors for array 
definition. The following PixScanner settings were entered into the program: 
Resolution of 3000x2208 pixels, 10x Zoom, Jpeg quality 90, and rows and columns 3. 
Finally, the sample identifier was entered into the program, and the area of tissue to be 
imaged was confirmed using the stepper motor increments. These settings generate a 9-
image array of a representative section of the tissue sample. This array definition 
process was then repeated for each tissue sample imaged.  
For polarized light images, several additional steps were included in the 
imaging process. Following the brightfield imaging described above, the EPLIS filter 
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was set to 3 degrees, the LBD filter was opened, the ND6 filter closed, the Exposure 
Time was set to 150, and the light setting was set to maximum. White balance was 
performed, to ensure the embedded particles appeared white for verification. At this 
time, the image array programming and performance was repeated to collect the same 
9-image array to correspond with the brightfield images.  
2.5.3 Image Analysis 
Brightfield images of both H&E and immunohistochemical staining were 
visually scored for the presence of inflammation (histiocytes and giant cells) and 
increased blood vessels. These characteristics were scored with a simple 1 for yes and 
0 for no, and the totals for each sample were collected and compared.  
Computer-assisted image analysis was performed using ImageJ from the 
National Institutes of Health (NIH). First, a customized macro for determining the 
percentage of the image that contained tissue sample, shown in Figure 6 below, was 
run on all images.  
 
 
 
Figure 6: Tissue area percentage macro from ImageJ. This macro was used on all acquired images 
to determine the percentage of actual tissue sample present in the image field. 
 
 
 
These values were used to normalize the percentage of positively stained area, which 
was also determined using a custom ImageJ macro. For each set of images, a known 
positive response was manually processed to determine the threshold mask value that 
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best represented the area of positive immunohistochemical staining. Figure 7, below, 
shows the macro used for evaluation of 4-HNE images.  
 
 
 
Figure 7: Immunohistochemical stain percentage macro. This macro was used in ImageJ to 
determine the percentage of tissue that was positively stained for the antibody of interest. 
 
 
In the fourth line of the macro, the threshold value used for 4-HNE was 120. The 
following values were used for the remaining immunohistochemical stains: COX2 115, 
HMGB1 125, iNOS 105, and NT 119. Once these threshold values were determined, 
all images for that antibody were processed in a batch, and the resulting values were 
collected, normalized to area percentage, and then averaged and compared.  
Embedded polyethylene particle number was determined using a customized 
macro in NIH ImageJ, shown in Figure 8 below. The resulting particle number results, 
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reported in number per image, were then converted to number per mm2 of tissue using 
a measured conversion factor of 0.5µm/pixel.  
 
 
 
 
Figure 8: Particle analysis macro from ImageJ. This macro was used to determine the number of 
polyethylene particles in each tissue image. 
 
 
 
2.6 Genetic and Protein Array Selection 
 The proposed genetic and protein array designs were based on the 
immunohistochemistry results, specifically those from the low and moderate osteolysis 
groups. These groups represent the early onset osteolytic condition, which is the 
intended time point for diagnosis and treatment. These results were then coupled with 
extensive research into studies regarding related genes and proteins for the design of 
the most comprehensive and potentially accurate genetic and protein arrays.  
2.7 Statistical Analysis 
To determine whether the immune response (inflammation, 
immunohistochemical positive response) was proportional to implant-related variables 
(polyethylene wear particle number, osteolytic severity), statistics were performed 
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using XLSTAT (Addinsoft). Data were collected from 432 images for each 
immunohistochemical antibody stain, H&E stain, and polarized light image. Statistical 
significance was evaluated using Pearson’s correlation coefficient and principle 
component analysis.  
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3. DESIGN 
3.1 Summary of Design Process 
Background information on osteolysis and implant wear-mediated 
inflammation, the problem statement, and the specific aims for this design project were 
given in the Introduction section (Chapter 1). The final design process was an iterative 
process conducted within five distinct phases, which are shown in Figure 9 below.  
 
 
 
Figure 9: Design process diagram. 
 
 
In the first phase, human periprosthetic tissues were collected from THR 
patients with varying levels of osteolytic severity. The second phase involved 
histomorphological analysis of the tissue samples to determine the presence of 
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inflammation and wear debris for study eligibility. Once tissues were determined study 
eligible, immunohistochemical analysis for five specific osteolysis and oxidative 
stress-related biomarkers was performed for phase III. Based on these results and 
extensive literature review, phase IV involved the design of a genetic array that would 
be used to evaluate activated osteolysis-related mechanisms in THR revision tissues, 
by identifying consistently upregulated or dowregulated genes in these tissues. Finally, 
the last phase of the design process was carried out in a manner similar to phase IV, 
culminating in the design of a protein panel for the early diagnosis of osteolysis. 
3.2 Rationale for Array and Panel Design Selection 
Design criteria and element inclusion for the genetic array and protein panel 
were drawn from literature on biological and molecular changes in periprosthetic 
tissues from several models. The genetic array contains 27 genes chosen for their 
involvement in osteoblastogenesis and osteoclastogenesis, as well the involvement of 
oxidative stress in osteolysis. The 28 proteins and oxidized products included in the 
antibody panel were chosen based on the same criteria. Additionally, the genetic array 
contains 4 PCR controls and one housekeeping gene control, while the protein panel 
includes two protein detection controls. The inclusion of these elements functions as a 
method of normalizing the results to patient individuality. Numerous genes and 
proteins were considered for inclusion, and the 32 genes and 30 proteins were selected 
after several relevant articles suggested their involvement in bone resorption and 
osteolysis. Detailed analysis of each gene and protein selected for the final design 
prototypes can be found in the Discussion section (Chapter 5).  
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3.3 Criteria and Constraints for Designed Devices 
3.3.1 Design Criteria 
 Several criteria were included in designing the genetic array and protein panel 
for evaluation of patient tissue and serum samples. These criteria include ease and 
safety of use, compatibility with industry equipment, inclusion of internal controls, and 
result of a more sensitive detection system for osteolysis than current radiographic 
analysis.  
First, these devices must be simple to use, easy to understand, and safe to 
operate by clinical lab personnel, and both clinicians and surgeons will incorporate 
them into their treatment regimen for the benefit of their patients. Secondly, the 
designed devices must be compatible with industry equipment. The genetic array is 
designed to include 32 elements for evaluation, filling a standard 32-well plate that can 
be found in most laboratories. Similarly, the protein panel was designed to include 30 
elements for evaluation, making it comparable with the standard protein evaluation 
panel offered by Zyomyx, Inc.  Thirdly, the arrays were designed to include several 
internal control elements, such as PCR control indicators and housekeeping genes and 
proteins, which allow for normalization of the expression patterns for each individual 
patient, as well as confirming that the sample was analyzed properly. Finally, the 
designed protein panel must provide an accurate diagnosis of osteolysis at a rate of 
75% or better in order to be considered viable, which this design should provide. In 
addition, this design must provide a more sensitive diagnostic and predictive test for 
identifying implant osteolysis than the current radiographic analysis approach.  
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3.3.2 Design Constraints 
Similarly, several constraints were considered in designing the genetic array 
and protein panel for evaluation of patient tissue and serum samples. These constraints 
include overall cost, long-term viability of the panel antibodies, sensitivity of detection 
in serum samples, and FDA approval.  
First, the overall cost of constructing and using the designed array and panel 
must be considered. The current designs allow for one plate or device to be used for 
each patient. Conversely, each patient requires a full plate to be used, which may 
eventually increase overall costs; however, it is expected that the number of factors will 
be reduced to five critical components. The designs will be optimized through clinical 
trials to select the most relevant markers, thus reducing the overall number of plates 
that must be used and reducing the overall cost. Another consideration is the long-term 
viability and storage of the antibodies for the protein panel. External contaminants, 
improper storage before use, and age of the antibodies can have severe negative effects 
on the capacity of the antibodies to detect their targets in the patient samples. 
Expiration dates and clear, concise storage information must be provided with the 
designed devices. A third constraint that was considered during the design process is 
the need to verify that the selected proteins and products will be detectable in the 
patient serum samples, as is explained in the Verification section below (Section 3.4). 
Finally, these devices would be subject to FDA approval for clinical use with THR 
patients, which would extend the cost and time before the devices could be used in a 
clinical setting.  
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3.4 Validation and Verification Process 
It is important to note that the genetic array and protein panel are preliminary 
design prototypes, which are subject to change upon evaluation of THR revision tissue 
and serum samples. To verify and validate the designed devices, research and clinical 
studies using THR revision tissue and serum sample from patients with varying levels 
of osteolysis need to be performed using the design genetic array and protein panel. 
These analyses can be used to determine their effectiveness for both tissue and serum 
samples, as well as determining the efficacy and accuracy of the designed devices.  
For the genetic array design, a lack of upregulation or downregulation in the 
selected gene expression would question their potential involvement in osteolysis. For 
the protein panel, in addition to a lack of regulation patterns in the chosen elements, 
some proteins in the panel may be upregulated in the revision tissues, but whether a 
corresponding increase in serum will be detected is unknown. If the chosen genes and 
proteins do not exhibit consistent regulation patterns in both the THR revision tissue 
and serum samples, other elements will be chosen for evaluation.  
As a secondary and more cost effective verification and validation for the study 
as a whole, additional immunohistochemical analyses on THR revision tissue samples 
should be performed. First, the expression patterns of the five selected 
immunohistochemical biomarkers should be evaluated across a larger THR revision 
patient population, with even distribution of patients in each osteolysis severity group. 
This should allow for the establishment of a tighter distribution range, and provide a 
more accurate idea regarding the expression of each target during each stage of 
osteolysis. On the same note, these markers should be compared between tissues 
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retrieved from both historical and highly crosslinked PE implant components. This 
would establish the universality of the designed genetic array and protein panel for all 
THR patients.  
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4. RESULTS 
This section is organized into four main subsections: histomorphology 
screening, immunohistochemistry, genetic array design, and diagnostic protein panel 
development. Results from brightfield and polarized light imaging of H&E stained 
study tissues are presented in Section 4.1. Brightfield images of 
immunohistochemically stained study tissues, positively stained area percentage 
values, and statistical analysis of these values are presented in Section 4.2. The 
proposed designs of the genetic array and diagnostic protein panel are reported in 
Sections 4.3 and 4.4, respectively. 
4.1 Histomorphology Screening 
 In this study, the hypothesis that that wear-mediated inflammation is a 
precursor to osteolysis was tested. Initially, samples were screened for the presence of 
an inflammatory response as a part of inclusion criteria. Inflammation was present in 
all osteolytic tissues, and to a much lesser extent in control tissues. Representative 
brightfield and polarized light images showing inflammation and polyethylene (PE) 
wear particles, respectively are provided in Figure 10.   
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Figure 10: Inflammation and PE particle analysis. A: Brightfield image of a representative H&E 
stained tissue. Orange arrow indicates area of inflammation (magnified inset). B: Polarized light 
image of PE particles. The orange arrow indicates an area with inflammatory cells, specifically 
histiocytes as shown in the magnified image inset. Co-localized in this area were numerous PE 
wear particles. Images acquired at 100x magnification, inset 1000x magnification. 
  
Severely osteolytic tissues (Group 1) contained 5.7 ± 1.8 particles per mm2 of 
tissue. Moderately osteolytic tissues (Group 2) contained 182.4 ± 145.0 particles/mm2, 
with a large outlier of 1615 particles in one tissue sample. The increased particle 
number for this patient is most likely due to the 25-year length of implantation, 
compared to the 10-15 year range for the other patients in Group 2. Low osteolytic 
tissues (Group 3) contained 10.6 ± 1.9, and non-osteolytic tissues (Group 4) contained 
1.5 ± 0.3 particles/mm2 of tissue. The overall decrease in the number of wear particles 
in severely osteolytic tissues was the direct result of increased tissue necrosis, which 
facilitates the loss of previously embedded PE wear particles. 
4.2 Immunohistochemistry  
The main hypothesis of this study was that wear-mediated inflammation 
triggers the production of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS), and that these species contribute to the development of osteolysis. Five 
immunohistochemical markers were evaluated using primary antibodies for osteolysis 
A B 
100 µm 100 µm 
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(high mobility group protein B1, HMGB1), reactive oxygen species enzyme and 
product (cyclooxygenase-2, COX2; 4-hydroxynonenal, 4-HNE), and reactive nitrogen 
species enzyme and product (inducible nitric oxide synthase, iNOS; nitrotyrosine, 
Nitro, NT). The presence of these markers in osteolytic tissues indicates that oxidative 
stress plays a role in the development of osteolysis.  
Immunohistochemistry showed that all five osteolysis, ROS and RNS enzymes, 
and ROS/RNS products were present in osteolytic tissues. Exemplar images of all five 
markers are shown in Figure 11 below. All five markers were associated with regions 
of inflammation localized around blood vessels. These markers were visible in control, 
non-osteolytic tissues and localized to inflammatory regions, but the amounts were 
decreased by approximately 20%. The exception was the presence of the iNOS product 
NT, which based on previous reports does not correlate with the severity of osteolysis; 
but it is observed in areas of wear debris-mediated inflammation, explaining its 
presence in the control non-osteolytic tissues [60]. 
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Figure 11: Immunohistochemistry for osteolysis and oxidative stress markers. Representative 
images of positive immunohistochemical staining. A: 4-HNE accumulation, ROS product; B: 
COX2 expression, ROS enzyme; C: HMGB1 expression, osteolysis marker; D: iNOS expression, 
RNS enzyme; E: NT accumulation, RNS product. Blue arrows indicate inset location. Images 
acquired at 100x magnification, insets 1000x magnification. 
 
 
 
Images were collected for each study sample, and the images were analyzed 
using a customized NIH ImageJ macro. This program determined the positively stained 
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area of each tissue image, which was normalized to tissue area, determined using a 
customized NIH ImageJ macro. The average value for each 9-image array was 
calculated, and those values are reported in Table 1 for severely osteolytic tissues in 
Group 1. The average and standard error of the mean for Group 1 are reported at the 
bottom of Table 1.  
 
 
Table 1: Immunohistochemistry image analysis results for Group 1 (Severe Osteolysis). Positively 
stained area percentages for each immunohistochemical marker. 
Group 1 4-HNE COX2 HMGB1 iNOS NT 
H105 C5 7.6 7.4 0.8 0.8 1.4 
H105 C6 10.8 3.8 6.1 0.5 5.2 
H105 Average 9.2 5.6 3.4 0.7 3.3 
H203 C1 0.0 0.0 2.6 0.0 1.9 
H203 C2 0.0 0.0 0.0 0.0 0.0 
H203 C3 1.0 0.0 2.5 0.0 0.0 
H203 C4 0.0 0.0 0.8 0.0 0.1 
H203 Average 0.2 0.0 1.5 0.0 0.5 
H405 C1 2.7 0.0 0.9 0.8 3.0 
H405 C2 0.3 0.0 1.5 0.2 0.8 
H405 C3 3.9 2.1 2.9 0.3 3.8 
H405 C4 6.1 5.8 6.8 4.9 1.9 
H414 Average 3.2 2.0 3.1 1.5 2.4 
H414 C1 8.2 3.3 2.6 1.0 4.7 
H414 C2 0.1 1.1 6.1 2.3 1.2 
H414 Average 4.2 2.2 4.3 1.7 2.9 
H681 C1 5.5 2.7 32.6 1.8 1.0 
H681 C2 0.0 0.0 0.0 0.0 0.0 
H681 Average 2.8 1.4 16.3 0.9 0.5 
H687 C1 7.3 9.8 8.0 4.1 3.7 
H687 C2 8.4 9.6 7.8 1.6 1.2 
H687 Average 7.8 9.7 7.9 2.9 2.4 
Group 1 Average 4.6 3.5 6.1 1.3 2.0 
Group 1 SEM 0.8 0.9 1.4 0.2 0.3 
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 Similarly, the average positively stained area value for each 9-image array in 
Group 2, as well as the average and standard error of the mean are reported in Table 2. 
 
 
Table 2: Immunohistochemistry image analysis results for Group 2 (Mod. Osteolysis). Positively 
stained area percentages for each immunohistochemical marker. 
Group 2 4-HNE COX2 HMGB1 iNOS NT 
H328 C 0.0 0.3 0.0 0.0 0.0 
H416 C1 0.0 0.0 0.0 0.1 0.0 
H416 C2 5.4 6.2 1.6 0.4 0.0 
H416 C3 0.0 6.2 2.5 0.0 1.4 
H416 Average 1.8 4.1 1.4 0.2 0.5 
H438 C1a 20.8 1.1 5.1 4.4 4.0 
H438 C1b 13.9 16.2 14.3 10.6 16.5 
H438 C2 0.0 4.6 10.7 6.1 0.0 
H438 C3 7.0 16.6 2.6 0.7 4.3 
H438 Average 10.4 9.6 8.1 5.5 6.2 
H455 C1 9.6 4.4 3.8 0.3 4.8 
H455 C2 3.3 0.0 6.7 3.7 7.4 
H455 C3 0.0 0.0 7.6 0.0 0.0 
H455 Average 4.3 1.5 6.0 1.3 4.1 
Group 2 Average 4.1 3.9 3.9 1.7 2.7 
Group 2 SEM 1.4 1.3 1.2 0.8 0.9 
 
 
 
This image analysis process was repeated again for the low osteolysis tissues in 
Group 3 and the non-osteolytic control tissues in Group 4. Table 3, shows the average 
positively stained area for each tissue sample, in addition to the average and standard 
error of the mean for Group 3. Similarly, the image analysis results for Group 4 are 
reported in Table 4.  
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Table 3: Immunohistochemistry image analysis results for Group 3 (Mild Osteolysis). Positively 
stained area percentages for each immunohistochemical marker. 
Group 3 4-HNE COX2 HMGB1 iNOS NT 
H165 C1 9.3 4.5 6.1 1.5 5.0 
H165 C2 17.3 5.3 6.7 3.4 6.5 
H165 C3 4.2 0.0 1.0 0.0 3.7 
H165 Average 10.3 3.3 4.6 1.7 5.1 
H206 C1 5.8 2.5 2.4 0.0 1.4 
H206 C2 0.0 0.6 0.0 0.2 0.0 
H206 Average 2.9 1.5 1.2 0.1 0.7 
H280 C1 12.6 5.1 2.1 0.0 5.5 
H280 C2 4.1 3.2 2.4 0.0 1.0 
H280 Average 8.3 4.1 2.3 0.0 3.3 
H297 C1 5.3 0.0 2.9 0.4 1.7 
H297 C2 5.0 0.0 2.3 0.0 1.1 
H297 C3 4.6 0.0 5.0 0.8 5.5 
H297 Average 5.0 0.0 3.4 0.4 2.7 
H347 C 5.3 2.1 9.0 1.7 4.5 
H449 C1 4.1 2.4 2.8 0.4 0.0 
H449 C2 0.4 0.0 0.0 0.5 3.3 
H449 Average 2.3 1.2 1.4 0.5 1.7 
H473 C1 12.2 6.0 7.6 1.7 3.7 
H473 C3a 17.6 4.6 1.9 0.0 1.4 
H473 C3b 10.2 2.8 2.2 0.0 3.9 
H473 C4 10.5 4.7 0.0 0.0 3.3 
H473 Average 12.6 4.5 2.9 0.4 3.1 
Group 3 Average 6.7 2.4 3.5 0.7 3.0 
Group 3 SEM 0.9 0.4 0.7 0.2 0.4 
 
 
 
Table 4: Immunohistochemistry image analysis results for Group 4 (control, no osteolysis). 
Positively stained area percentages for each immunohistochemical marker. 
Group 4 4-HNE COX2 HMGB1 iNOS NT 
H254 C1 2.1 0.3 1.2 0.0 2.4 
H254 C2 2.8 1.2 1.2 0.0 2.5 
H254 Average 2.5 0.7 1.2 0.0 2.4 
H460 C1 3.1 0.0 0.0 0.4 2.5 
H460 C2 1.7 2.3 3.9 0.5 1.2 
H460 Average 2.4 1.1 1.9 0.5 1.9 
Group 4 Average 2.4 0.9 1.6 0.2 2.2 
Group 4 SEM 0.0 0.1 0.3 0.2 0.2 
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 Average positively stained area percentage and standard error of the mean 
values for all five immunohistochemical markers each of the four patient groups are 
summarized in Table 5 and Figure 12.  
 
Table 5: Summary of immunohistochemistry image analysis results. Average positive area 
percentages and standard error of the mean (SEM) reported for each marker, for each osteolytic 
severity group. 
 4-HNE COX2 HMGB1 INOS NITRO 
Group 1 Average 4.58 3.48 6.07 1.28 2.01 
Group 1 SEM 0.84 0.89 1.36 0.25 0.30 
Group 2 Average 4.14 3.89 3.89 1.75 2.68 
Group 2 SEM 1.37 1.25 1.16 0.77 0.89 
Group 3 Average 6.67 2.40 3.54 0.68 3.00 
Group 3 SEM 0.90 0.44 0.69 0.16 0.36 
Group 4 Average 2.41 0.94 1.57 0.24 2.15 
Group 4 SEM 0.03 0.14 0.25 0.17 0.21 
 
 
 
 
A correlation between the amount of HMGB1 expression and osteolytic 
severity was observed. HMGB1 was highest in Group 1, containing severely osteolytic 
tissues, while Group 4, non-osteolytic control tissues, exhibited the least amount of 
HMGB1 expression. Linear regression of the data showed a R2 correlation value of 
0.94, indicating a strong correlation between HMGB1 and osteolysis severity. 
Additionally, while it appears that the increase in 4-HNE expression for Group 3 may 
indicate the onset of osteolysis, a larger sample size would need to be evaluated to 
confirm this trend.  
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Figure 12: Mean positive area percentages for all five immunohistochemical markers. Positive 
area means for each marker, grouped by osteolytic severity (Group 1: Severe; Group 2: Moderate; 
Group 3: Low; Group 4: Control). Error bars represent standard error of the mean. HMGB1 
trendline R2 = 0.94.  
 
 
 
Pearson’s correlation coefficient and principle component analysis (PCA) were 
performed on individual patient data. As a part of these analyses, Bartlett’s test for 
sphericity was also performed to test the null hypothesis that Pearson’s correlation 
matrix is an identity matrix. This test confirms that enough data points are available for 
effective comparisons and statistical analysis.  
PCA and Pearson’s correlation results for Group 1 are shown in Table 6. Data 
for this group passed the Bartlett’s sphericity test (p<0.0001). PCA shows that all 8 
variables fall within the F1 and F2 columns, or that variability is accounted for within 
these two groups. 4-HNE, COX2, iNOS, inflammation, and blood vessels are all 
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grouped in F1, indicating these factors are related to each other. Likewise, HMGB1, 
NT, and particle number are related, and grouped together in F2. Pearson’s coefficient 
analysis shows that ROS enzyme COX2 is correlated with its oxidized product 4-HNE, 
while inflammation correlates with all immunohistochemical markers except NT. This 
seems to be contrary to previous reports that observe NT localized to areas of 
inflammation, as described previously [60]. However, the high degree of necrosis in 
this group may account for the lack of correlation. Interestingly, PE particle number is 
correlated with HMGB1, suggesting a relationship between particle number and 
osteolysis.  
 
 
 
 
Table 7 shows PCA and Pearson’s correlation results for Group 2, and the 
Bartlett’s sphericity test was p<0.0001. PCA showed that all 8 variables fell within the 
F1 and F2 columns. All variables except blood vessels were grouped in F1, indicating 
these factors are related to each other. Pearson’s coefficient analysis showed HMGB1 
and iNOS correlated with inflammation and particle number. Whereas, COX2 and the 
oxidized product 4-HNE show no correlation with each other or other factors in this 
group, unlike their correlation with each other and inflammation in Group 1.  
Table 6: PCA and Pearson's coefficient analysis for Group 1. Columns F1 and F2 represent PCA 
outcomes, with remaining columns representing Pearson's coefficients of correlation. Inflam: 
inflammation, BVs: blood vessels, Part #: particle number. 
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PCA and Pearson’s correlation results for Groups 3 and 4 are shown in Table 8 
and Table 9, respectively. Data from Group 3 passed the Bartlett’s sphericity test 
(p=0.004). Data from Group 4 did not pass the Bartlett’s sphericity test, and therefore 
no statistical significance was observed within this group.  
 
 
 
 
 
 
 
Table 7: PCA and Pearson's coefficient analysis for Group 2. Columns F1 and F2 represent PCA 
outcomes, with remaining columns representing Pearson's coefficients of correlation. Inflam: 
inflammation, BVs: blood vessels, Part #: particle number. 
Table 8: PCA and Pearson's coefficient analysis for Group 3. Columns F1 and F2 represent PCA 
outcomes, with remaining columns representing Pearson's coefficients of correlation. Inflam: 
inflammation, BVs: blood vessels, Part #: particle number. 
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PCA for Group 3 shows that 6 of the 8 variables fall within the F1 and F2 
columns, or more specifically, that most of the variability in the data is accounted for 
within these two groups. All five immunohistochemical markers and inflammation are 
grouped together in F1, signifying these factors are related to each other. Neither blood 
vessels nor particle number were grouped into F1 or F2, meaning their variability is not 
accounted for in the two main variable groups.  
Pearson’s coefficient analysis for Group 3 showed that ROS enzyme COX2 is 
correlated with its oxidized product 4-HNE, while both of these oxidative stress 
markers are correlated with inflammation. This correlation suggests a relationship 
between inflammation and ROS activation in the early onset of osteolysis. 
Additionally, HMGB1 is correlated with both iNOS and NT, suggesting RNS and 
ROS, play a role in early onset osteolysis.  
 Finally, Table 10 shows PCA and Pearson’s correlation results for the entire 
data set as a whole; Bartlett’s sphericity test (p<0.0001). PCA showed that all 
immunohistochemical markers except HMGB1, inflammation and particle number are 
Table 9: PCA and Pearson's coefficient analysis for Group 4. Columns F1 and F2 represent PCA 
outcomes, with remaining columns representing Pearson's coefficients of correlation. Inflam: 
inflammation, BVs: blood vessels, Part #: particle number. 
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grouped together in F1, indicating these factors are related to each other. While 
vascularity is within F2, HMGB1 variation is not accounted for by either F1 or F2. 
However, this was expected since HMGB1 showed the most variation with osteolytic 
severity (Figure 12).  
 
 
  
 
Immunohistochemistry showed that all five osteolysis, ROS and RNS enzymes, 
and ROS/RNS products were present in osteolytic tissues. All five markers were 
associated with regions of inflammation localized around blood vessels, and Pearson’s 
correlation analysis confirmed a relationship between each immunohistochemical 
marker and inflammation (Table 10). PE particle number was significantly related to 
the expression of all immunohistochemical markers except 4-HNE. Inflammation was 
correlated with increased vascularity, the route of inflammatory cell infiltration into the 
tissue. NT also correlated with inflammation in the group statistical analysis, 
supporting its association with inflammation [60]. Additionally, COX2 expression 
correlated with its oxidized product 4-HNE, and iNOS expression correlated with its 
Table 10: PCA and Pearson's coefficient for the entire data set. Columns F1 and F2 represent PCA 
outcomes, with remaining columns representing Pearson's coefficients of correlations. Inflam: 
inflammation, BVs: blood vessels, Part #: particle number. 
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oxidized product NT, which supports activation and involvement of both ROS and 
RNS in tissue from THRs revised for osteolysis.  
Overall, both severe and moderate osteolysis showed a significant correlation 
between particle number and HMBG1. Severe osteolysis was also correlated with the 
presence of 4HNE, COX2, iNOS, and vascularity. Interestingly, low or early osteolysis 
showed correlations with 4HNE and COX2, whereas in the increased osteolysis groups 
this relationship was replaced by correlations of HMGB1 with iNOS.  
4.3 Genetic Array Design 
Based on the presence of osteolysis and oxidative stress markers in tissues from 
patients revised for early and late osteolysis, a genetic array was designed to further 
evaluate mechanisms involved in mediating osteolysis. The genetic array design is 
based on the immunohistochemistry results and known osteoclast, osteoblast, and 
oxidative stress-related genes. After careful consideration of the immunohistochemistry 
results and several review articles [34, 42, 66-68], the genetic array in Table 11 was 
designed.  
This designed array contains 27 genes chosen for their involvement in the 
differentiation and function of osteoblasts and osteoclasts, as well the involvement of 
oxidative stress in osteolysis. A disruption in the balance between osteoblast and 
osteoclast formation and activation is the underlying mechanism driving osteolysis, 
supporting the decision to focus on genes related to these two cell types. Additionally, 
there are 4 PCR control indicators and one housekeeping control gene in the array, 
bringing the total number of array elements to 32.  
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It is important to note that this is a preliminary design prototype, which is 
subject to change upon evaluation of THR revision tissues. If the chosen genes are not 
upregulated or downregulated indicating their potential involvement in osteolysis, 
other genes will be chosen for evaluation. More information regarding the specifics and 
rationale for gene selection is included in the Discussion section.  
 
 
 
Table 11: Proposed genetic array for osteolysis diagnosis. 27 genes chosen for osteolytic activity, 1 
housekeeping control gene, and 4 PCR control indicators. 
BMP5 Osteoclast-related NOX2 
Osteoclast-specific 
Oxidative Stress-related 
BMP6 Osteoclast-related NOX3 Oxidative Stress-related 
CTR 
Osteoclast Calcitonin 
Receptor 
NOX4 
Osteoclast-specific 
Oxidative Stress-related 
DCST1 Osteoclast-related NOX5 Oxidative Stress-related 
DCST2 Osteoclast-related SOD1 Oxidative Stress-related 
MMP9 Osteoclast-related SOD2 Oxidative Stress-related 
OPG Osteoclast-related SOD3 Oxidative Stress-related 
RANKL Osteoclast-related HMG1 HMGB1 Gene 
TRAP/ACP5 Osteoclast-related NOS2 iNOS Gene 
CAT Antioxidant NOS3 NOS Gene 
GPX1 Antioxidant PTGS2 COX2 Gene 
BMP2 Osteoblast-related GAPDH 
Housekeeping Gene 
(Control) 
BMP4 Osteoblast-related ACTB Loading Control 
FGF2 Osteoblast-related HGDC Activator Control 
FGF18 Osteoblast-related RTC 
Reverse Transcription 
Control 
NOX1 Oxidative Stress-related PPC Positive PCR Control 
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A design with 32 individual elements is desirable for convenience of use and 
standardization. Genetic arrays are generally performed in a 96-well plate, and it is 
desirable to run a sample in triplicate to standardize the results.  In this proposed 
genetic array design, the 96-well plate is suitable for analyzing a patient sample with 
32 elements in triplicate. Additionally, the test results are standardized, since the entire 
test will be performed on the same plate, at the same time, and under the same 
conditions. An additional consideration is that this genetic array design reduces cost 
and waste, as only one plate and one test iteration are required per patient sample.  
4.4 Diagnostic Protein Panel Design  
This study also hypothesizes that a protein and oxidative stress product panel 
can be designed for the antibody-based diagnosis of osteolysis. The protein panel is 
based on the immunohistochemistry results and the assumption that the designed 
genetic array would result in the upregulation of osteoclast and oxidative stress-related 
genes. The protein panel is presented in Table 12.  
The protein panel contains 28 proteins or oxidized products chosen for their 
involvement in osteoclastogenesis and osteoblastogenesis, as well as oxidative stress 
and osteolysis. Additionally, there are 2 protein detection controls in the panel, 
bringing the total number of elements to 30. Several products available on the market, 
such as the Zyomyx BioChip, evaluate 30 proteins on a single panel. This design 
remains competitive with currently available products by being compatible with 
existing protein profiling systems. With this design, the test results can be standardized, 
since the entire test is performed on the same array, and under the same conditions.  
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As with the genetic array, it is important to note that this is a preliminary design 
prototype, which is subject to change upon further evaluation of THR revision tissue 
and serum samples. Some proteins in the panel have been chosen based on the 
expectation of upregulation in tissues, but a corresponding increase in the level of these 
proteins in serum is unknown. Additionally, some of the proteins selected are secreted, 
and therefore expected to be present in the serum, while membrane associated proteins 
are non-secreted and may only be present in the tissues. If the chosen proteins are not 
upregulated in both the tissue and serum samples, other proteins will be chosen for 
evaluation. More information regarding the specifics and rationale for proteins 
selection is included in the Discussion section.  
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Table 12: Proposed diagnostic protein array design. 28 proteins and products chosen for osteolytic 
diagnosis, and 2 proteins included for protein detection control. 
BMP-5 Osteoclast-related BMP-2 Osteoblast-related 
BMP-6 Osteoclast-related BMP-4 Osteoblast-related 
CATK Osteoclast-related FGF-2 Osteoblast-related 
MMP-9 Osteoclast-related FGF-18 Osteoblast-related 
NTX Osteoclast-related 4-HNE 
Oxidative Stress 
Product 
OPG Osteoclast-related COX2/PTGS2 Oxidative Stress Protein 
RANKL Osteoclast-related HMGB1 Oxidative Stress Protein 
TRAP5 Osteoclast-related iNOS Oxidative Stress Protein 
GPX1 
Anitoxidant & 
Osteoclast-related 
NOX1 Oxidative Stress Protein 
CAT Antioxidant NOX2 
Osteoclast-specific 
Oxidative Stress Protein 
GRX5 
Oxidative Stress 
Suppressor 
NOX4 
Osteoclast-specific 
Oxidative Stress Protein  
CCL18 
Alternative Macrophage 
Activation 
PGE2 
Oxidative Stress 
Product 
CHIT1 
Alternative Macrophage 
Activation 
SOD1 Oxidative Stress Protein 
M-CSF 
Osteolytic Fibroblast 
Secretion 
GAPDH Control (for tissue) 
ALP Osteoblast-related ALB Control (for serum) 
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5. DISCUSSION 
This is the first study to evaluate the involvement of ROS, the combination of 
ROS and RNS, and HMGB1, an oxidative stress responsive and pro-osteoclastic factor, 
in PE wear debris-mediated THR osteolysis. Only one previous study has specifically 
evaluated the presence of ROS in aseptic loosened THR revision tissues, but this study 
was preliminary and broad in terms of establishing the presence of ROS [45]. Two 
studies have looked at the role of RNS, but the results for iNOS and NT production 
were inconsistent [59, 60]. Other studies that have focused on inflammatory mediators 
as indicators for the severity of osteolysis in both tissues and serum have met with little 
success despite the presence of inflammation [34, 36, 69]. The goal of this study was to 
evaluate the involvement of oxidative stress in the development of THR osteolysis in 
response to PE wear debris, since many of the inflammatory mediators are known to 
induce ROS and RNS production.  
5.1 Immunohistochemistry Results 
  Immunohistochemical analysis of several oxidative stress responsive proteins, 
HMGB1, ROS enzyme COX2 and RNS enzyme iNOS, as well as the ROS product 4-
HNE and RNS product NT was performed to determine whether oxidative stress is 
involved in the development of osteolysis in periprosthetic tissues. All five 
immunohistochemical markers were associated with regions of inflammation in all 
tissues, including the control non-osteolytic tissues. However, expression levels in the 
control tissues were markedly reduced compared to the osteolytic tissues. 4HNE, 
COX2, and iNOS expression were correlated with severe osteolysis, suggesting the 
involvement of both ROS and RNS in severely osteolytic tissues. In addition, severe 
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and moderate osteolysis groups showed significant correlation between HMGB1 and 
particle number, supporting a relationship between wear debris-mediated immune 
response, oxidative stress, and the development of osteolysis. Furthermore, these 
results suggest that HMGB1 is a more sensitive indicator of osteolysis, as compared to 
the current radiographic determination of osteolysis. 
Several groups have looked at iNOS expression in revision tissues. While not 
observed in this study, Stea and colleagues showed that iNOS expression was directly 
proportional to the extent of osteolysis [59]. However, in agreement with the present 
study, Stea reports high levels of iNOS expression in severely osteolytic tissues [59]. 
The late increase in iNOS expression may represent an effort to downregulate 
osteoclastogenesis in severely osteolytic tissues [70]. Brandi and colleagues found that 
osteoblasts, osteoclasts, and osteoclast precursors synthesize nitric oxide, which 
inhibits osteoclast activity [70-72].  
In contrast to Stea et al. and similar to our own findings, Puskas and colleagues 
did not observe any significant difference in iNOS expression between loose, osteolytic 
and loose, non-osteolytic THR revision tissues, but did observe a significant increase in 
the amount of iNOS expression in revision tissues compared to primary THR synovial 
tissues (p<0.05) [59, 60]. iNOS produces nitric oxide, which can react with superoxide 
anion (ROS) to form peroxynitrite; this RNS reacts with susceptible protein tyrosine 
groups to form NT, which accumulates in the tissue over time [60]. Similar to the study 
by Puskas, we observed NT in periprosthetic tissues, regardless of the extent or 
severity of osteolysis. Specifically, NT accumulation was significantly increased in 
THR revision tissues compared to primary THR synovial tissues (p<0.05), however the 
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NT expression between loose, osteolytic THR revision tissues and loose, non-
osteolytic THR revision tissues was nearly the same [60]. In general, NT was observed 
in areas of wear debris-mediated inflammation [60], which are increased in both 
osteolytic and non-osteolytic tissues surrounding loosened implants, thus explaining 
the presence of NT in our control non-osteolytic tissues. This group also suggested that 
NT may prove to be a useful marker for implant loosening, rather than being specific 
for osteolysis.   
The increased presence of COX2 in osteolytic tissues is in agreement with 
several animal studies that implicate COX2 expression in the development of 
osteolysis in response to titanium wear debris [55, 57, 73]. Both Zhang and Wei 
suggested that COX2 inhibitors have the potential to be used as therapeutic agents [57, 
73], and later Im and group demonstrated this potential using rabbit models [55].  
One of the most significant outcomes of this study is the finding that oxidative 
stress plays a role in the development of osteolysis in periprosthetic tissues. This is 
based on the increased expression of two oxidative stress responsive ROS and RNS 
enzymes and the accumulation of their products in retrieved tissues with low, 
moderate, and severe osteolysis. HMGB1 expression was evaluated in this study as it is 
an oxidative stress responsive protein that is released by apoptotic osteoblasts and it 
promotes osteoclastogenesis [53], implicating its importance in evaluating osteolysis. 
This protein has not been evaluated in THR revision tissues, making this study unique. 
HMGB1 was present in THR revision tissues and, as shown in Figure 12, increases in 
direct proportion to osteolytic severity, suggesting the levels of this protein may be 
more sensitive in detecting osteolysis compared to the less sensitive radiographic 
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measurements. Additionally, HMGB1 was significantly correlated with particle 
number in severe and moderate osteolysis, supporting the connection between wear 
debris-mediated inflammation and osteolysis. Taken together, the increased presence of 
COX2, its product 4-HNE, and HMGB1 during the earliest stages of osteolysis indicate 
that together these markers have the potential to identify early osteolysis.   
5.2 Genetic Array and Diagnostic Protein Panel Element Selection  
As discussed previously, this study includes the design of a genetic array and 
protein panel for the early diagnosis of THR osteolysis. The proposed designs are 
primarily based on the immunohistochemistry results and osteoblast/osteoblast factors, 
along with several review articles discussing the genes associated with these factors 
and oxidative stress. Both the genetic array and protein panel are preliminary design 
prototypes, which are subject to change upon evaluation of THR revision tissue and 
serum samples. However, background and rationale for element selection can be found 
in the following sub-sections. The genes and proteins chosen for the designs can be 
broken into five main categories: osteoclast-related, osteoblast-related, oxidative stress-
related, inflammation-related, and controls.  
5.2.1 Osteoclast-related Genes and Proteins 
The first group of genes and proteins incorporated into the design includes 
those specifically related to osteoclastogenesis, activation and promotion of bone 
resorption. These pro-osteolytic genes and proteins include: BMP-5, BMP-6, CATK, 
CTR, DCST1 and 2, MMP9, NTX, OPG, RANKL, and TRAP.  
Bone morphogenetic proteins (BMP) 5 and 6 were included, as they have been 
shown to play an important role in bone homeostasis and osteoclast differentiation 
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[68]. Wutzl and colleagues treated mouse bone marrow cells with recombinant BMP-5 
and BMP-6, and found that both proteins induced a dose-dependent increase in 
osteoclast tartrate-resistant acid phosophatase (TRAP) activity up to 1ng/mL. This 
study showed that BMP-5 and -6 work together in a biphasic fashion to induce 
osteoclastogenesis in murine in vitro studies [68].  
Five osteoclast-related elements are included in the array and protein designs 
that are not redundant to each, but may yield interesting and relevant information 
relating to osteoclastic activity in the patient sample. Osteoclast calcitonin receptor 
(CTR) characterizes mature osteoclasts, and the resorptive activity of osteoclasts is 
negatively regulated by calcitonin [42, 74]. Takahashi and colleagues found that CTR 
mRNA expression is detectable in osteoclast precursors, and the protein is expressed in 
the late stages of osteoclast differentiation associated with multinucleation [74]. 
Dendritic cell-specific transmembrane protein (DC-STAMP), encoded by DCST1 and 
DCST2 genes, is essential for osteoclastogenesis and osteoclast multinucleation [34, 
75]. Matrix metallopeptidase 9 (MMP9), a matrix degrading enzyme and osteoclast 
marker, plays a major role in the recruitment of osteoclasts in early bone formation 
[76]. In a previous study of synovial tissues from THR patients revised for osteolysis, 
the expression of DC-STAMP and MMP9 was increased by nearly 10-fold compared 
to osteoarthritic controls [34]. Cathepsin K (CATK), similar to MMP9, is a matrix 
degrading enzyme secreted by activated osteoclasts and plays a role in periprosthetic 
bone resorption [77]. Shen and colleagues showed that human tissues with cells 
containing phagocytosed PE particles, as well as bone surface cells, exhibited increased 
levels of CATK mRNA and protein expression [77]. While the encoded proteins may 
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not be detectable in serum samples, genetic and proteomic evaluation of these factors is 
relevant in determining the presence of osteoclasts in revision tissues.  
N-telopeptides of type-I collagen (NTX), which are released from resorbed 
bone surfaces by osteoclasts, have also been implicated in implant loosening in hip 
arthroplasty [67, 78]. Wilkinson and researchers evaluated NTX levels in serum and 
urine samples taken from patients with cemented THR with and without femoral 
loosening. Their results showed that patients with femoral loosening experienced a 
53% increase in this bone-related factor, and that this increase was statistically 
significant. Although it was determined that NTX is not a sensitive marker of aseptic 
loosening, researchers suggested its relevance in evaluating the effectiveness of 
antiresorptive therapies [78]. On the other hand, if used in conjunction with the 
proteins selected for study, the panel of proteins as a whole should improve the 
sensitivity of detecting early osteolysis. 
Another pair of genes and proteins that work together in bone remodeling are 
receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin 
(OPG), the main effectors of bone homeostasis and resorption [25, 34, 79]. OPG is 
secreted by osteoblasts and acts as a “decoy” receptor for RANKL, blocking its 
binding to its normal receptor, RANK [25]. Ritchlin and colleagues describe the 
relationship between RANK and RANKL as the main signaling pathway responsible 
for the increase in osteoclast differentiation, activity and increased bone resorption 
[79]. Interestingly, significantly decreased levels of OPG have been observed in 
periprosthetic tissues from THR patients revised for osteolysis compared to tissues 
from patints with osteoarthritis [34]. Although, RANKL was not significantly 
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increased, a decrease in OPG would contribute to a relative increase in bone resorption 
[34]. In the current study, the inclusion of these two gene and protein pairs allows for 
an assessment of the RANKL/OPG ratio, with increased ratios signifying an osteolytic 
condition [34].  
Finally, osteoclast-specific tartrate-resistant acid phosphatase (TRAP) 5 protein, 
encoded by the ACP5 gene, is an osteoclast marker and has been shown to be elevated 
under osteolytic conditions [34]. As described above, BMP-5 and BMP-6 increase 
TRAP expression and osteoclast activity in murine models [68]. Additionally, TRAP 
expression is significantly increased in synovial tissues from THR patients with 
osteolysis compared to samples from osteoarthritic patients without osteolysis [34]. 
Inclusion of this secreted, matrix-modifying enzyme in the genetic array and protein 
diagnostic panel will provide information related to the degree of osteoclastoegenesis 
and potential bone resorption.  
5.2.2 Osteoblast-related Genes and Proteins 
The next group of genes and proteins included in the genetic array and 
diagnostic protein panel relate specifically to osteoblasts, the bone producing cells. 
Evaluation of these genes and proteins would yield information regarding their activity 
under osteolytic conditions, as new bone formation is overwhelmed by osteoclast-
driven bone resorption. Nonetheless, these elements may also be increased when 
compared to normal conditions, as the osteogenic response is attempting to re-establish 
a balance in bone remodeling. Pro-osteoblastic genes and proteins include: ALP, BMP-
2, BMP-4, FGF-2, and FGF-18.  
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Alkaline phosphatase (ALP), an osteoblast marker, is associated with an 
increase in osteoblastogeneis and bone formation [80, 81]. In most studies, ALP 
expression is used to characterize osteogenic activity and osteoblast populations [80, 
81]. As such, evaluation of this protein on a diagnostic protein panel would determine 
if ALP is decreased in relationship to resorption activity.  
Bone morphogenetic proteins (BMP) 2 and 4 have been implicated in bone 
remodeling activities, specifically bone formation activities [34, 68, 82]. Rawadi and 
group have shown that introducing pluripotent mesenchymal stem cells and osteoblast 
cells to BMP-2 induces ALP expression, osteoblast differentiation and mineralization 
in vitro [82]. Although Wutzl found that BMP-2 is capable of promoting 
osteoclastogenesis, this protein has been shown to be one of the most efficacious for 
promoting osteogenic activity in vitro [68, 83]. Additionally, studies show BMP-4 
expression is significantly decreased (p<0.05) in osteolytic synovial tissues when 
compared to controls, suggesting a downregulation of osteogenic activity [34]. Thus, 
BMP-2 and -4 expression profiles in a genetic array and diagnostic protein panel 
should yield information regarding osteogenic activity.  
Finally, fibroblast growth factors (FGF) 2 and 18 regulate osteoblast activity 
and bone formation [34, 84, 85]. In a study with murine models, Montero and 
colleagues found that FGF-2 deficient mice exhibited decreased bone volume, 
mineralization, and bone formation [84]. These results suggest that FGF-2 is an 
important player in osteogenesis. In 2008, Koulouvaris and researchers found that 
FGF-18, a key regulator of osteogenesis through the promotion of osteoblast 
differentiation, was significantly downregulated in osteolytic hip synovial tissues when 
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compared to osteoarthritic primary tissue samples [34]. Additional research by 
Shimoaka and group showed a compensatory relationship between FGF-2 and FGF-18, 
both having very similar effects on osteoblast proliferation and bone formation [85]. 
Similar to the BMPs, FGF-2 and -18 expression profiles in a genetic array and 
diagnostic protein panel should yield information regarding osteogenic activity.  
5.2.3 Oxidative Stress-related Genes and Proteins 
 The largest group of genes and proteins that comprise the array and diagnostic 
panel are the oxidative stress-related elements. Immunohistochemistry confirmed that 
oxidative stress plays a major role in osteolysis, prompting the evaluation of oxidative 
stress-related mRNA and protein expression for osteolytic diagnosis. These elements 
include: 4-HNE, COX2/PTGS2, HMGB1/HMG1, iNOS, NOS2 and 3, NOX1-5, 
PGE2, SOD1-3, TNF-α, CAT, GPX1, and GRX5.  
 Those proteins (and their protein-encoding genes) associated with the early 
osteolysis immunohistochemical markers, COX2 (COX2/PTGS2), HMGB1 (HMG1), 
and iNOS (NOS2 and 3), are included in the genetic array and diagnostic panel based 
on their association with osteolysis and oxidative stress from this study. As discussed 
previously, these proteins are present in osteolytic tissues and their expression is 
upregulated in response to oxidative stress. Additionally, HMGB1 is an 
osteoclastogenic cytokine that promotes osteoclast differentiation through its 
interaction with receptor for advanced gylcation endproducts (RAGE) and toll-like 
receptors (TLR) 2 and 4 [54]. Although not proteins, the COX2 products 4-HNE and 
prostaglandin E2 (PGE2) can be detected with antibodies, which is the detection 
method of the protein array. These products are of major interest because circulating 
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levels can be detected when they are increased in tissues. As shown in the 
immunohistochemical results, secreted 4-HNE is present in revision THR tissues and 
should be detectable in the serum. COX2 expression by osteoblasts generates PGE2, 
which promotes bone resorption [86]. Previous studies have shown that PGE2 release 
associated with titanium wear particle ingestion contributes to periprosthetic osteolysis 
[87].  
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) 1 
through 5 have all been implicated in oxidative stress and bone remodeling [42, 50, 
66]. NOX1 activation in osteoclast precursor cells is largely involved in 
osteoclastogenesis [42, 66]. NOX2, described as a phagocytic homologue to NOX4 
and an oxygen sensor, also play a role in oxidative stress and bone resorption [88]. 
Orient and colleagues describe NOX2 and NOX4 in murine osteoclasts as enzymes 
that fulfill a compensatory role in supporting oxidative stress-induced bone resorption 
[88]. Both NOX1 and NOX4 mRNA have been found in low to moderate levels in 
murine osteoclasts, suggesting the involvement of these proteins in osteoclast activity 
[49, 66, 89, 90]. NOX3 has been detected in low levels in skull bone, and NOX5 was 
shown to be minimally present in bone marrow [66]. Based on the review of the NOX 
family by Bedard and Krause implicating NOX in osteoclast differentiation and 
activity [66], the inclusion of these NOX elements in the designed array and panel is 
appropriate in assessing the severity of osteolysis.  
 Superoxide dismutases (SOD) 1-3, which convert superoxide anion to hydrogen 
peroxide, have been shown to play a role in increased oxidative stress and bone loss 
[42]. Smietana and colleagues showed that SOD1-knockout mice exhibited decreased 
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bone mineral density, decreased bone stiffness, and increased levels of oxidative stress 
[91]. Additionally SOD2 and SOD3 levels have been shown to increase in the presence 
of ROS and oxidative stress [92, 93]. Increased expression of these three SOD 
elements may indicate a response to increased ROS and oxidative stress levels, 
signifying the possibility of an osteolytic condition.  
 Finally, the proposed genetic array and protein panel designs also include 
several additional antioxidants, which actively reduce or control the level of oxidative 
stress. Catalase (CAT) and glutathione peroxidase 1 (GPX1) are antioxidants 
responsible for degrading hydrogen peroxide [42]. When upregulated in osteoclasts, 
GPX1 prevents RANKL-induced osteoclast formation, thus downregulating bone 
resorption [42]. Glutaredoxin 5 (GRX5) is another enzyme responsible for removing 
hydrogen peroxide and it is abundantly expressed in bone, as such it assists in reducing 
oxidative stress [42]. When expressed in large amounts, GRX5 prevents the 
accumulation of ROS and prevents ROS-induced osteoblast apoptosis, thus 
maintaining bone formation [42]. Inclusion of these elements in the array and 
diagnostic panel may yield important information about the stage of osteolysis, as these 
factors would be expected to increase in response to oxidative stress and potentially as 
osteolysis becomes more severe.  
5.2.4 Inflammation-related Proteins 
The proposed protein panel design also includes three inflammation-related 
proteins, all of which have been implicated in the development of osteolysis [34, 35, 
94]. These inflammatory proteins include: CHIT1, CCL18, and M-CSF.  
 	  
60	  
Chitotriosidase (CHIT1) and chemokine ligand 18 (CCL18) are proteins 
expressed during activation of the alternative macrophage pathway [34, 35]. 
Koulouvaris and researchers found both CHIT1 and CCL18 to be significantly 
upregulated in late stage osteolytic THR patients as opposed to control osteoarthritic 
patients [34]. These findings effectively establish a connection between periprosthetic 
loosening and alternative activation of macrophages, a condition previously suggested 
by Purdue in 2008 [34, 35]. Thus, CHIT1 and CCL18 are included as markers of 
alternative macrophage activation and osteolysis in the diagnostic protein panel.  
Macrophage colony-stimulating factor (M-CSF), a cytokine required for 
osteoclast differentiation in conjunction with RANKL, was included in the diagnostic 
panel as a means of fully characterizing the condition of bone remodeling [94]. 
Described as an osteoclastogenic cytokine, M-CSF maintains osteoclast precursor cells 
and promotes their differentiation by inducing TNF-α and RANK gene expression 
[94]. Kitaura and colleagues showed that M-CSF inhibition in murine models blocks 
TNF-α-induction of macrophages, leading to osteoclastogenesis and bone resorption, 
suggesting its importance in the development of the osteolytic condition [94, 95]. 
Therefore, expression of this protein in the diagnostic panel should point to the 
potential for osteolysis.  
5.2.5 Control Genes and Proteins 
Five genes were included in the array serve as controls for various aspects of 
PCR evaluations. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was chosen 
as a normalization control; it is a housekeeping gene that is generally present in all 
tissues [96]. Four other controls were chosen for inclusion, based on their use by 
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QIAGEN and SABiosciences in commercial genetic array programs: beta-actin 
(ACTB) as a loading control, I-2-hydroxyglutaryl-CoA dehydratase (HGDC) as an 
activator control, reverse transcriptase control (RTC), and positive PCR control (PPC).  
Additionally, two proteins were chosen to serve as controls and normalization 
of the protein array results. First, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was chosen as a normalization control for tissue samples [96]. Secondly, 
albumin (ALB) was chosen as a control for serum samples [97]. These proteins can be 
used to normalize protein expression for both tissue and serum samples.  
5.3 Limitations  
Although this study yielded interesting results, there are several limitations that 
must be considered with the analyses. These limitations include the evolution of hip 
replacement materials, the nature of revision surgeries, availability of properly 
maintained surgical tissue samples, variability of human tissues, and image analysis 
software.  
One of the inclusion criteria for this study was that the revised implant must be 
of what is considered historical PE, which was replaced in clinical settings by highly-
crosslinked PE in 1998 [8]. Therefore, most of the patient population for this study 
underwent THR >10 years prior to the revision surgery. Additionally, these historical 
PE components have been shown to generate more and larger wear debris particles 
[98], and also elicit a more pronounced and complex foreign body response in 
periprosthetic tissues [9]. These factors must be taken into consideration when 
evaluating the degree of osteolytic response and PE wear debris observed in the study 
tissues. However, this group of patients serves as an important first step in evaluating 
 	  
62	  
the biological factors associated with osteolysis, and there are still a number of patients 
with functional historical THR components.  
The human tissue samples themselves also present several limitations to the 
study. First, humans vary in their genetic, biological and chemical makeup, which 
affects their inflammatory responses. Another consideration that must be made is that 
all study tissues are revision tissues, suggesting that complications with the implant had 
arisen. As such, it stands to reason that all retrieval tissues will exhibit some degree of 
wear debris-induced or general inflammation, which alters the chemistry of those 
tissues [36]. Healthy hip capsular tissues, biopsies from patients with functional THR 
implants, and cadaver tissues were unavailable for analysis, so inclusion of these 
groups as controls for baseline levels of immunohistochemical markers was not 
possible. Instead, this study relied on comparisons with tissues retrieved from short-
term hip revisions with no osteolysis, which exhibit a small amount of inflammation. 
Importantly, these tissues experienced the same trauma and association with the 
implant material as osteolytic tissues, making them appropriate controls. Although 
osteolysis was not indicated for the control patients, poor osseointegration due to 
inflammation, osteoclast activation, or inadequate osteoblast activity [9] may influence 
the levels of study markers in the control tissues. Overall, the presence of these 
markers in control tissues suggests that these markers are relevant for detecting implant 
complications and as such compliment the goals of this study to identify osteolytic 
markers. 
Additionally, surgeon compliance with tissue retrieval protocols is a limiting 
factor. Surgeons did not indicate tissue orientation or surfaces that were in contact with 
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the implant, which makes it difficult to standardize the tissue regions selected for 
analysis. To overcome these issues, regions for evaluation were selected from all of the 
tissues. Tissue heterogeneity is another issue that must be considered, as this study 
required the use of 12 serial tissue sections. As the distance from the implant interface 
increases, the degree of inflammatory and immunohistochemical response in the tissue 
may vary [36]; although, the use of 6µm sections minimizes this effect.  
Finally, use of technology and human input presents an interesting challenge to 
this study. ImageJ image processing software was used in this study, which has 
recently proven inferior to the newer ImagePro Plus image processing software. 
ImagePro Plus allows for analysis of tissue staining density, while ImageJ reports the 
area of stained tissue. Additionally, the area data determinations rely on subjective 
human input to determine the appropriate threshold level, which is not an exact science 
and may vary from user to user. Nonetheless, the results of this study generally agree 
with previous reports, and the preliminary ImagePro Plus results, and are therefore 
considered valid.  
5.4 Future Work 
 Several recommendations can be made for future work related to this study. 
Expression patterns of these immunohistochemistry markers should be evaluated 
across a much larger patient group. This should help to establish a tighter standard 
error of the mean, and give a more accurate idea of the degree of expression in each 
stage of osteolysis. On the same note, these markers should be compared between 
tissues retrieved from both historical and highly crosslinked PE implant components. 
This would establish the universality of the designed genetic array and protein panel 
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for all THR patients.  
Both research and clinical studies should be performed using the designed 
genetic array and protein panel. With known osteolytic and non-osteolytic tissue 
samples, the efficacy and accuracy of these designed devices can be evaluated. In 
addition, the analyses can be used to determine their effectiveness on both tissue and 
serum samples. Some proteins in the panel design have been chosen based on the 
expectation of their upregulation in tissues, but serum upregulation is unknown. 
Osteolytic tissue samples retrieved from the implantation site would be expected to 
contain most of the osteolytic markers, whereas not all of the factors may be 
sufficiently elevated in the blood to be detected. If the chosen proteins are not 
upregulated in both the tissue and serum samples, other proteins will be chosen for 
evaluation. Ultimately, evaluation of clinical samples from primary THR patients 
immediately after and at various times post-surgery would determine the overall 
effectiveness of the protein panel for use as a serum screening tool. Finally, if 
additional studies confirm the involvement of oxidative stress, then this pathway could 
be targeted for the development of therapeutic interventions.  
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6. CONCLUSION 
 Inflammation was present in all tissues, with low levels of inflammation in 
control tissues. Additionally, all five immunohistochemical markers evaluated were 
observed in osteolytic tissues. 4HNE, COX2, and iNOS expression were correlated 
with severe osteolysis, suggesting COX2 activation and the production of ROS in 
severely osteolytic tissues. Severely as well as moderately osteolytic tissues showed a 
significant correlation between particle number and HMGB1 expression, which is an 
oxidative stress responsive and osteoclastogenic protein [54]. This correlation supports 
the role of wear debris-mediated oxidative stress in the development of osteolysis, and 
the linear relationship of HMGB1 with the severity of osteolysis suggests that 
measuring the levels of this protein may be more sensitive than radiography in 
detecting osteolysis and implant loosening. Low osteolysis correlated with 4-HNE and 
COX2 expression, whereas this relationship was replaced by correlations of HMGB1 
with iNOS in increased osteolysis. The confirmed presence of ROS and RNS enzymes 
and products indicates oxidative stress is involved in the development of osteolysis in 
periprosthetic tissues.  
 A genetic array and diagnostic protein panel have been designed for evaluation 
of periprosthetic tissue and blood serum samples retrieved from THR patients to 
determine if osteolysis is present. The design of these osteolysis-specific prototype 
devices was guided by the immunohistochemistry results, analysis of several primary 
study and review articles, and commercially available products. Additional clinical 
sample analyses are necessary to determine the appropriateness of the selected 
elements, and to facilitate adjustments to the design elements. Once validated, the 
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designed protein panel could be used for both earlier and more effective diagnosis of 
osteolysis, and the appropriate genes, proteins, and pathways could be targeted to treat 
oxidative stress and osteolysis in THR patients. 
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APPENDIX A: Study Patient Clinical Information Summary 
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Group 1 – Severe Osteolysis         
1 PE Wear, Osteolysis Y Acetabular Y 15.66 67 M 
2 Loosening Y Acetabular Y 11.47 Not Available F 
3 Acetabular Loosening Y 
Acetabular 
Zones II & 
III; Femoral 
Zones II & 
VI 
Y 17.61 54 M 
4 
Loose 
Acetabular, PE 
Wear 
Y 
Zones I-III 
Acetabular; 
Greater 
Trochanter 
Y 19.80 45 M 
5 
Osteolysis 
(periacetabulum, 
proximal femur) 
and Polywear 
Y 
Peri-
acetabulum 
and 
proximal 
femur 
Y 15.68 76 M 
6 
Acetabular 
Loosening, PE 
Wear, 
Osteolysis 
Y Acetabular Y 16.02 70 M 
Group 2 – Moderate Osteolysis       
1 
Left hip 
osteolysis and 
wear 
Y Femoral Y 14.99 59 M 
2 Periprosthetic fracture (femur) Y 
Proximal 
Femoral Y 10.80 59 M 
3 Loosening  Y 
Femoral 
Zones I & 
VII 
Y 15.90 73 F 
4 
Loose 
Acetabular, 
Subsidence 
Y 
Acetabular 
Zones I-IV; 
Femoral 
Zones I, II, 
VI & VII 
Y 25.04 77 M 
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Group 3 – Low Osteolysis         
1 Loosening, PE Wear Y 
Retro-
acetabular 
and ischial 
N 20.17 75 F 
2 PE Wear, Instability Y Acetabular N 5.08 63 F 
3 Osteolysis, PE Wear Y Right Hip N 15.78 56 M 
4 
Acetabular 
Loosening, 
Protrusion 
Y Acetabular N 18.51 69 F 
5 Wear and Lysis Y 
Zone II 
acetabular; 
Greater 
Trochanter 
N 17.96 46 F 
6 PE Wear Y Zone III Acetabular N 15.10 63 M 
7 Loosening and Lysis Y Acetabular N 19.20 72 M 
Group 4 - Control Group           
1 Loosening N N/A N 2.93 62 F 
2 
Subluxation, 
impingement, 
cup malposition 
N N/A N 5.17 71 F 
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 APPENDIX B: High Mobility Group Protein B1 (HMGB1) Data Sheet 
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APPENDIX C: Cyclooxygenase-2 (COX2) Data Sheet 
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APPENDIX D: Inducible Nitric Oxide Synthase (iNOS) Data Sheet 
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APPENDIX E: 4-Hydroxynonenal (4-HNE) Data Sheet 
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APPENDIX F: Nitrotyrosine (NT) Data Sheet 
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